Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on &#8805; 1 line of endocrine therapy: systematic review and meta-analysis.

Huang, Xiewei; Yu, Yushuai; Luo, Shiping; Fu, Wenfen; Zhang, Jie; Song, Chuangui

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis.

Huang, Xiewei; Yu, Yushuai; Luo, Shiping; Fu, Wenfen; Zhang, Jie; Song, Chuangui.

Afiliación

Huang X; Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001, Fuzhou, Fujian Province, China.
Yu Y; Breast Surgery Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China.
Luo S; Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001, Fuzhou, Fujian Province, China.
Fu W; Breast Surgery Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China.
Zhang J; Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001, Fuzhou, Fujian Province, China.
Song C; Breast Surgery Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China.

BMC Cancer ; 24(1): 205, 2024 Feb 13.

Article en En | MEDLINE | ID: mdl-38350924

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: BMC Cancer / BMC cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google